Degradation of chondroitin sulfateby the gut microbiota of Chinese persons
Degradation of chondroitin sulfateby the gut microbiota of Chinese persons
复制标题
中国人肠道菌群对硫酸软骨素的降解
DOI：
--
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Xin Wang
中科院分区：
文献类型：
--
作者：
Qingsen Shanga;Yeshi Yin;Liying Zhu;Guoyun Li;Guangli Yu;Xin Wang
硫酸软骨素（chondroitin sulfate，CS）是一种口服抗骨关节炎的药物，但其在人体肠道菌群中的降解情况尚不清楚。在本研究中，CSA（CS药物的主要成分）的人体肠道微生物群的降解概况进行了研究，从六个健康的受试者。每个人的微生物群具有不同的降解活性，但在所有情况下UA-GalNAc 4S都是最终产物。为了阐明这一现象背后的机制，从每个人的微生物群中分离出不同的CSA降解细菌并测试CSA降解。除多形拟杆菌J1、多形拟杆菌82和卵形拟杆菌E3外，还分离到一株新的环孢菌素A降解菌Clostridium hathewayi R4。有趣的是，从每个人的肠道微生物群中鉴定出至少两种不同的CSA降解物种。可以预见的是，这些功能性细菌也具有不同的降解速率，但仍然产生相同的最终产物UA-GalNAc 4S。此外，人粪便分离株对CSC、CSD和CSE产生不同的降解谱，表明CS可以容易地被不同的微生物聚生体代谢到不同的程度，这可能有助于解释CS在OA治疗中的生物利用度差和个体间疗效不均等的原因。
Oral preparations of chondroitin sulfate (CS) have long been used as anti-osteoarthritis (anti-OA) drugs.However, little is known about the degradation of CS by human gut microbiota. In the present study,degradation profiles of CSA (the main constituent of CS drugs) by the human gut microbiota from sixhealthy subjects were investigated. Each individual’s microbiota had differing degradation activities, butUA-GalNAc4S was the end product in all cases. To elucidate the mechanisms underlying this phe-nomenon, different CSA-degrading bacteria were isolated from each individual’s microbiota and testedfor CSA degradation. In addition to Bacteroides thetaiotaomicron J1, Bacteroides thetaiotaomicron 82 andBacteroides ovatus E3, a new CSA-degrading bacterium, Clostridium hathewayi R4, was isolated and charac-terized. Interestingly, at least two different CSA-degrading species were identified from each individual’sgut microbiota. Predictably, these functional bacteria also had differing degradation rates, but still gen-erated the same end product, UA-GalNAc4S. In addition, the human fecal isolates produced differentdegradation profiles for CSC, CSD, and CSE, suggesting that CS could be readily metabolized to varyingextents by diverse microbial consortiums, which may help to explain the poor bioavailability and unequalefficacy of CS among individuals in OA treatment.